Anticoagulation After TAVR in Patients with Atrial Fibrillation

Primary Recommendation

• The European Society of Cardiology recommends direct oral anticoagulants (DOACs) over vitamin K antagonists (warfarin) for stroke prevention in patients with atrial fibrillation after TAVR 1
• The European Society of Cardiology guidelines explicitly recommend DOACs in preference to warfarin in eligible patients with atrial fibrillation undergoing cardioversion and for thromboembolic risk reduction 1

Antiplatelet Therapy Considerations

• The American College of Cardiology recommends stopping all antiplatelet therapy and treating with an oral anticoagulant alone (DOAC preferred) when considered safe from post-operative bleeding perspective, typically 3 to 14 days after surgery 2
• Anticoagulation alone (without antiplatelet therapy) should be used after the immediate post-operative period 2

Specific DOAC Selection

• The American College of Cardiology explicitly states that ticagrelor is not recommended as part of antithrombotic therapy in TAVR patients requiring oral anticoagulation due to higher bleeding risk 3

Timing of Anticoagulation Initiation

• The European Heart Rhythm Association recommends restarting NOACs 48-72 hours postoperatively in procedures with high bleeding risk, but as soon as possible when safe 4
• Resume full-dose oral anticoagulation 48-72 hours post-operatively, or earlier if bleeding risk is acceptable 4

Warfarin as Alternative

• If DOACs are contraindicated, the American Heart Association recommends warfarin with target INR 2.0-2.5 for the first 3 months post-TAVR in patients requiring anticoagulation, with possible transition to a DOAC after 3 months 5

Monitoring Requirements

• The American College of Cardiology recommends echocardiography before discharge for baseline valve function, repeat at 30 days, and then at least annually to monitor for complications 6
• Perform echocardiography at 30 days and annually, with ECG monitoring for new-onset atrial fibrillation 6